Award Data

PROJECT SUMMARY Substance use disorder (SUD) is a significant public health challenge, and it has been estimated that its effects on healthcare, work productivity, and criminal justice costs the US over $600 billion annually. Engagement with the clinical care team is critical to an individual’s path to SUD recovery; however, limited capacity of and access to addiction treatment providers and tra ...

Project Summary/Abstract Alzheimer’s disease (AD) affects more than six million Americans currently and is projected to affect 14 million at a cost of $1.2 trillion in 2050. Despite its tremendous impacts and the limited influence of pharmacological therapies, attention has been brought to non-pharmacological interventions as promising therapeutic strategies for the prevention of cognitive decli ...

PROJECT SUMMARY Glaucoma is the leading cause of irreversible blindness, impacting 80 million people worldwide. The only proven approach to prevent vision loss in glaucoma is the reduction of intraocular pressure (IOP), which is most commonly achieved by topical medications. Once daily (QD) prostaglandins are a typical first-line therapy, though the need for adjunctive therapy with other drug clas ...

Project Summary Abstract Cardiovascular Implantable Electronic Devices (CIEDs) like a Permanent Pacemaker or Implantable Defibrillator are implanted in over 3 million Americans, with the average age of implantation in the 60s, 40% ≥ 70 years old, and 28% ≥ 80 years old. When a patient presents to the Emergency Department (ED) with an unknown CIED, reprogramming of the device is often necessary ...

Abstract DUB Biologics is developing a therapeutic for the prevention and treatment of corneal scarring through knockdown of a novel target that has been shown to be central to the fibrotic response leading to corneal opacification. Corneal opacification severely impairs the vision of 4.2 million people around the world, 5.1% of the total blind population. Monocular scarring is far more common, af ...

Abstract In the United States alone, more than three million peripherally inserted central catheters (PICCs) are placed each year to provide IV therapies, where in about half of cases navigation through the venous system is typically performed blind, or without navigation guidance. Improper PICC placement is relatively common, is costly, and has serious complications for critically-ill patients. U ...

Project AbstractOur overarching goal is to provide reliable and efficient tools that can be used in structure based drug discovery (SBDD). One crucial component of SBDD is to predict the structure of a drug molecule that binds to a protein involved in a certain disease. This is usually achieved using computer tools and the process consists of two steps, namely hit identification and lead optimizat ...

Project summary/abstractGlaucoma is the second leading cause of irreversible vision loss in Americans. Effective treatment requires the patient to take visual field tests over time, to monitor for progression of visual field loss. In many patients there is no progression, but when it occurs it must be detected as quickly as possible in order to save vision by using a more aggressive treatment. Pat ...

PROJECT SUMMARY It has been shown that conversations on end-of-life care focused on a patient’s goals of care can reduce psychological distress and anxiety and lead to improved quality of life, and potentially prolonged life, for patients living with serious illness. The Serious Illness Conversation Guide (SICG) is a validated and widely used framework for training the critical communication ski ...

ABSTRACT Delix Therapeutics is developing psychoplastogens, compounds that promote rapid and sustained neuroplasticity. This new class of compounds was identified by Delix founder, Professor David Olson (UC Davis). DLX-007 is a novel, potent psychoplastogen designed and inspired by known psychoplastogens Ibogaine and 5-MeO-DMT. Similar to these clinically effective compounds, DLX-007 promotes stru ...